Astellas bolsters urology pipeline through ASKA deal
This article was originally published in Scrip
Executive Summary
Astellas has acquired the exclusive global rights to a drug for the treatment of functional symptoms of benign prostatic hyperplasia (BPH) discovered by the Japanese firm ASKA Pharmaceutical.